Abbvie Inc.

  • Earnings Score
  • Safety Score
  • Market Cap $356.84B
  • PE 84
  • Debt $73.65B
  • Cash $5.52B
  • EV $424.96B
  • FCF $17.83B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$4.24B
EBIT$9.14B
ROE126%
ROA7%
FCF$17.83B
Equity$3.36B
Growth Stability45%
PE84.2
PEG-13.43
PB106.08
P/FCF20.01
P/S6.33
Price/Cash0.02
Debt/Equity21.89
Debt/FCF4.13
Net Margins8%
Gross Margins70%
Op. Margins16%
Earnings CAGR2%
Sales Growth YoY6%
Sales Growth QoQ4%
Sales CAGR12%
FCF CAGR16%
Equity CAGR9%
Earnings Stability0.04
Earnings Growth YoY-104%
Earnings Growth QoQ-102%
Earnings CAGR 5Y-6%
Sales CAGR 5Y8%
FCF CAGR 5Y6%
Equity CAGR 5Y-19%
Earnings CAGR 3Y-2%
Sales CAGR 3Y-2%
FCF CAGR 3Y-10%
Equity CAGR 3Y-39%
Market Cap$356.84B
Revenue$56.33B
Dividend Yield3%
Payout Ratio264%
Assets$135.16B
Total Debt$73.65B
Cash$5.52B
Shares Outstanding1.77B
EV424.96B
Earnings Score6%
Safety Score43%
Working Capital-13.17B
Current Ratio0.66
Gross Profit$39.43B
Shares Growth 3y-0%
Equity Growth QoQ-45%
Equity Growth YoY-68%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

SEC Filings

Direct access to Abbvie Inc. (ABBV) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Abbvie Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Abbvie Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 2%
Stability 4%
loading chart...

Abbvie Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Abbvie Inc..

= $544B
012345678910TV
fcf$18B$21B$24B$28B$32B$37B$43B$50B$58B$68B$78B$785B
DCF$19B$20B$21B$22B$23B$24B$26B$27B$29B$30B$302B
Value$544B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins23%23%19%17%24%10%20%20%9%8%8%
ROA-14%14%11%15%8%12%13%9%7%7%
ROE-128%104%-67%-96%35%74%68%46%126%126%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-5.613.923.035.565.564.022.773.014.134.13
Debt over Equity7.937.947.25-4.58-8.697.135.733.896.3921.8921.89
Growth Stability---100%100%73%100%100%52%45%45%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-12%10%16%2%38%23%3%-6%4%8%
Earnings YoY growth-15%-11%7%39%-42%152%3%-59%-12%-6%
Equity YoY growth-18%10%-266%-3%-260%18%12%-40%-68%-19%
FCF YoY growth--6%44%36%-0%31%31%10%-9%-19%6%